Lineage Cell Therapeutics (LCTX) EBITDA (2016 - 2025)
Historic EBITDA for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.8 million.
- Lineage Cell Therapeutics' EBITDA rose 140.62% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 5477.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 1316.06% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported EBITDA of -$3.8 million as of Q3 2025, which was up 140.62% from -$19.8 million recorded in Q2 2025.
- Lineage Cell Therapeutics' EBITDA's 5-year high stood at -$3.8 million during Q3 2025, with a 5-year trough of -$28.2 million in Q4 2021.
- In the last 5 years, Lineage Cell Therapeutics' EBITDA had a median value of -$6.5 million in 2025 and averaged -$7.8 million.
- Its EBITDA has fluctuated over the past 5 years, first tumbled by 38007.48% in 2021, then skyrocketed by 7648.91% in 2022.
- Lineage Cell Therapeutics' EBITDA (Quarter) stood at -$28.2 million in 2021, then soared by 76.49% to -$6.6 million in 2022, then increased by 4.17% to -$6.4 million in 2023, then rose by 19.68% to -$5.1 million in 2024, then increased by 25.91% to -$3.8 million in 2025.
- Its EBITDA stands at -$3.8 million for Q3 2025, versus -$19.8 million for Q2 2025 and -$6.5 million for Q1 2025.